Melissa A. Merritt, Ph.D., Joanne Kotsopoulos, Ph.D., Daniel W. Cramer, M.D., Sc.D., Susan E. Hankinson, Sc.D., Kathryn L. Terry, Sc.D., Shelley S. Tworoger, Ph.D.
Vol 98, Issue 3, Pages 687-691
To investigate whether Galactose-1-phosphate uridyl transferase (GALT) variant genotypes were associated with epithelial ovarian cancer risk and to determine if this association was modified by lactose intake.
Two prospective cohort studies and a case-control study.
992 cases and 1,050 population-based controls from a New England case-control study and 240 cases and 900 controls from the Nurses' Health Studies.
Main Outcome Measure(s):
Genotyping of the N314D variant and the 4-bp deletion (-119delGTCA) of GALT using the Taqman 5' nuclease assay. Duarte1 (D1) genotype individuals have a missense mutation (N314D) associated with normal GALT activity unless it occurs together with an associated 4-bp deletion leading to reduced GALT activity (Duarte2 or D2).
Logistic regression analysis identified no association between D1/D2 genotypes and ovarian cancer risk (pooled RR, 1.1 (95% CI, 0.8-1.5) for D1 and 1.0 (95% CI, 0.7-1.4) for D2). We did not observe a significant interaction between D1 and D2 genotypes in analyses stratified by level of lactose intake (Pinteraction ≥ 0.3).
D1 and D2 genotypes do not appear to play a role in the association between galactose intake, possible ovarian dysfunction and the link with ovarian cancer.
Read the full text at: http://www.fertstert.org/article/S0015-0282(12)00599-7/fulltext